We’re thrilled to welcome Dr. Murray A. Abramson as Chief Development Officer & announce our new Ophthalmology Clinical Advisory Board guiding ACDN-01 for #StargardtDisease. Big things ahead!
🔗 ascidian-tx.com/press-releas...
#RNAExonEditing #TeamAscidian #Biosky
🔗 ascidian-tx.com/press-releas...
#RNAExonEditing #TeamAscidian #Biosky
June 24, 2025 at 11:31 AM
We’re thrilled to welcome Dr. Murray A. Abramson as Chief Development Officer & announce our new Ophthalmology Clinical Advisory Board guiding ACDN-01 for #StargardtDisease. Big things ahead!
🔗 ascidian-tx.com/press-releas...
#RNAExonEditing #TeamAscidian #Biosky
🔗 ascidian-tx.com/press-releas...
#RNAExonEditing #TeamAscidian #Biosky
Today Ascidian and Forge Biologics unveiled our manufacturing partnership. Through the collaboration, Forge’s FUEL™ platform and cGMP services will produce AAV for ACDN-01, securing the clinical supply needed to advance into late-stage studies.
Learn more: 🔗 bit.ly/49vnvdf
Learn more: 🔗 bit.ly/49vnvdf
January 7, 2026 at 1:07 PM
Today Ascidian and Forge Biologics unveiled our manufacturing partnership. Through the collaboration, Forge’s FUEL™ platform and cGMP services will produce AAV for ACDN-01, securing the clinical supply needed to advance into late-stage studies.
Learn more: 🔗 bit.ly/49vnvdf
Learn more: 🔗 bit.ly/49vnvdf
On Friday, Ascidian Chief Development Officer, Murray Abramson, MD, MPH, shared updates on ACDN-01’s progress at the FFB Retinal Therapeutics Innovation Summit.
Full details: ascidian-tx.com/wp-content/u...
Full details: ascidian-tx.com/wp-content/u...
May 4, 2026 at 8:30 PM
On Friday, Ascidian Chief Development Officer, Murray Abramson, MD, MPH, shared updates on ACDN-01’s progress at the FFB Retinal Therapeutics Innovation Summit.
Full details: ascidian-tx.com/wp-content/u...
Full details: ascidian-tx.com/wp-content/u...
Attending #ASGCT2026?
Ascidian CDO Murray Abramson, MD, MPH, is presenting first-in-human safety data for #ACDN-01 in #StargardtDisease.
⏰ Today, 3:45-4:00 PM
📍 Room 258ABC (Level 2), Thomas M. Menino Convention & Exhibit Center
Ascidian CDO Murray Abramson, MD, MPH, is presenting first-in-human safety data for #ACDN-01 in #StargardtDisease.
⏰ Today, 3:45-4:00 PM
📍 Room 258ABC (Level 2), Thomas M. Menino Convention & Exhibit Center
May 12, 2026 at 2:54 PM
Attending #ASGCT2026?
Ascidian CDO Murray Abramson, MD, MPH, is presenting first-in-human safety data for #ACDN-01 in #StargardtDisease.
⏰ Today, 3:45-4:00 PM
📍 Room 258ABC (Level 2), Thomas M. Menino Convention & Exhibit Center
Ascidian CDO Murray Abramson, MD, MPH, is presenting first-in-human safety data for #ACDN-01 in #StargardtDisease.
⏰ Today, 3:45-4:00 PM
📍 Room 258ABC (Level 2), Thomas M. Menino Convention & Exhibit Center
Clinical milestones for ACDN-01 in #StargardtDisease: dose escalation complete in the STELLAR trial with pediatric expansion underway, and new STARPATH prescreening study now enrolling adult and pediatric patients.
Full details 🔗 ascidian-tx.com/wp-content/u...
Full details 🔗 ascidian-tx.com/wp-content/u...
May 4, 2026 at 1:02 PM
Clinical milestones for ACDN-01 in #StargardtDisease: dose escalation complete in the STELLAR trial with pediatric expansion underway, and new STARPATH prescreening study now enrolling adult and pediatric patients.
Full details 🔗 ascidian-tx.com/wp-content/u...
Full details 🔗 ascidian-tx.com/wp-content/u...
#ASGCT2026 is two weeks away — and we have new data to share.
Ascidian will present first-in-human safety data for ACDN-01 in #StargardtDisease, and data demonstrating the potential of our platform across multiple therapeutic areas.
See what's coming ➡️ ascidian-tx.com/wp-content/u...
Ascidian will present first-in-human safety data for ACDN-01 in #StargardtDisease, and data demonstrating the potential of our platform across multiple therapeutic areas.
See what's coming ➡️ ascidian-tx.com/wp-content/u...
April 28, 2026 at 12:22 PM
#ASGCT2026 is two weeks away — and we have new data to share.
Ascidian will present first-in-human safety data for ACDN-01 in #StargardtDisease, and data demonstrating the potential of our platform across multiple therapeutic areas.
See what's coming ➡️ ascidian-tx.com/wp-content/u...
Ascidian will present first-in-human safety data for ACDN-01 in #StargardtDisease, and data demonstrating the potential of our platform across multiple therapeutic areas.
See what's coming ➡️ ascidian-tx.com/wp-content/u...
#ICYMI, earlier this month Ascidian and Forge Biologics announced a manufacturing partnership to advance ACDN-01, our lead RNA exon editing candidate for #StargardtDisease.
Check out this BioProcess International article to learn more:
tinyurl.com/y6c434mv
Check out this BioProcess International article to learn more:
tinyurl.com/y6c434mv
Ascidian partners with Forge Biologics against Stargardt disease
The companies have entered a manufacturing partnership to advance Ascidian’s lead retinal candidate.
www.bioprocessintl.com
January 29, 2026 at 1:19 PM
#ICYMI, earlier this month Ascidian and Forge Biologics announced a manufacturing partnership to advance ACDN-01, our lead RNA exon editing candidate for #StargardtDisease.
Check out this BioProcess International article to learn more:
tinyurl.com/y6c434mv
Check out this BioProcess International article to learn more:
tinyurl.com/y6c434mv
That's a wrap on #ASGCT2026: First-in-human safety data for #ACDN-01 in #StargardtDisease. AI/ML-powered platform advances. Preclinical data in repeat expansion disorders.
Great science, great conversations.
We are thankful for this community and energized for what's next! #RNAExonEditing.
Great science, great conversations.
We are thankful for this community and energized for what's next! #RNAExonEditing.
May 15, 2026 at 10:56 PM
That's a wrap on #ASGCT2026: First-in-human safety data for #ACDN-01 in #StargardtDisease. AI/ML-powered platform advances. Preclinical data in repeat expansion disorders.
Great science, great conversations.
We are thankful for this community and energized for what's next! #RNAExonEditing.
Great science, great conversations.
We are thankful for this community and energized for what's next! #RNAExonEditing.
Why rewrite RNA instead of DNA? Ascidian CSO Robert Bell explains, and shares highlights from our first-in-human safety data for #ACDN-01 in #StargardtDisease. Watch his interview from #ASGCT2026 with Brad Loncar and @biotechtv.bsky.social.
➡️ www.biotechtv.com/post/asgct-2...
➡️ www.biotechtv.com/post/asgct-2...
ASGCT 2026: Ascidian Therapeutics is presenting initial human safety data from its RNA exon editing platform in a Stargardt disease trial
CSO Robert Bell describes the advantages of RNA exon editing he sees over DNA editing, and walks us through the safety data. With that in hand, which was in adult patients, the company is moving forwa...
www.biotechtv.com
May 14, 2026 at 2:12 PM
Why rewrite RNA instead of DNA? Ascidian CSO Robert Bell explains, and shares highlights from our first-in-human safety data for #ACDN-01 in #StargardtDisease. Watch his interview from #ASGCT2026 with Brad Loncar and @biotechtv.bsky.social.
➡️ www.biotechtv.com/post/asgct-2...
➡️ www.biotechtv.com/post/asgct-2...
Ascidian Therapeutics partners with Forge Biologics to develop ACDN-01, a gene therapy for Stargardt disease, leveraging Forge's cGMP manufacturing and proprietary technologies.
Read my full article below:
www.bioprocessintl.com/deal-making/...
Read my full article below:
www.bioprocessintl.com/deal-making/...
Ascidian partners with Forge Biologics against Stargardt disease
The companies have entered a manufacturing partnership to advance Ascidian’s lead retinal candidate.
www.bioprocessintl.com
January 15, 2026 at 10:58 AM
Ascidian Therapeutics partners with Forge Biologics to develop ACDN-01, a gene therapy for Stargardt disease, leveraging Forge's cGMP manufacturing and proprietary technologies.
Read my full article below:
www.bioprocessintl.com/deal-making/...
Read my full article below:
www.bioprocessintl.com/deal-making/...
Ascidian Successfully Completes Dose Escalation Phase of ACDN-01 for Stargardt Disease#USA#Boston#Stargardt_Disease#Ascidian_Therapeutics#ACDN-01
Ascidian Successfully Completes Dose Escalation Phase of ACDN-01 for Stargardt Disease
Ascidian Therapeutics has completed the adult dose escalation phase of the STELLAR trial for ACDN-01, targeting Stargardt disease. The study will now enroll pediatric participants.
third-news.com
May 4, 2026 at 11:19 AM
Ascidian Successfully Completes Dose Escalation Phase of ACDN-01 for Stargardt Disease#USA#Boston#Stargardt_Disease#Ascidian_Therapeutics#ACDN-01
Ascidian Therapeutics Showcases Breakthroughs in Stargardt Disease Treatments at ASGCT 2026#United_States#Boston#Stargardt_Disease#Ascidian_Therapeutics#ACDN-01
Ascidian Therapeutics Showcases Breakthroughs in Stargardt Disease Treatments at ASGCT 2026
Ascidian Therapeutics is set to present significant advancements in treating Stargardt disease and other genetic disorders at the ASGCT 2026 annual meeting.
third-news.com
April 28, 2026 at 11:19 AM
Ascidian Therapeutics Showcases Breakthroughs in Stargardt Disease Treatments at ASGCT 2026#United_States#Boston#Stargardt_Disease#Ascidian_Therapeutics#ACDN-01
Ascidian Therapeutics Strengthens Leadership with New CDO and Advisory Board for Stargardt Disease Treatment#United_States#Boston#Stargardt_Disease#Ascidian_Therapeutics#Dr._Murray_A._Abramson
Ascidian Therapeutics Strengthens Leadership with New CDO and Advisory Board for Stargardt Disease Treatment
Ascidian Therapeutics appoints Dr. Murray A. Abramson as CDO and forms an advisory board aimed at advancing ACDN-01 for Stargardt disease.
third-news.com
June 24, 2025 at 11:11 AM
Ascidian Therapeutics Strengthens Leadership with New CDO and Advisory Board for Stargardt Disease Treatment#United_States#Boston#Stargardt_Disease#Ascidian_Therapeutics#Dr._Murray_A._Abramson
Join us & The Carroll Center for the Blind this #WorldSightDay for the “Journey Through Vision Loss” event.
Hear from @fightblindness.bsky.social, mental health experts & advocates, plus updates on our #RNAExonEditing candidate ACDN-01 & the #STELLAR trial in #StargardtDisease.
🧷 bit.ly/42bSmsd
Hear from @fightblindness.bsky.social, mental health experts & advocates, plus updates on our #RNAExonEditing candidate ACDN-01 & the #STELLAR trial in #StargardtDisease.
🧷 bit.ly/42bSmsd
What's Next in Your Journey Through Vision Loss - The Carroll Center for the Blind
Join us for an empowering event dedicated to individuals experiencing vision loss, their families, and caregivers.
bit.ly
October 1, 2025 at 12:31 PM
Join us & The Carroll Center for the Blind this #WorldSightDay for the “Journey Through Vision Loss” event.
Hear from @fightblindness.bsky.social, mental health experts & advocates, plus updates on our #RNAExonEditing candidate ACDN-01 & the #STELLAR trial in #StargardtDisease.
🧷 bit.ly/42bSmsd
Hear from @fightblindness.bsky.social, mental health experts & advocates, plus updates on our #RNAExonEditing candidate ACDN-01 & the #STELLAR trial in #StargardtDisease.
🧷 bit.ly/42bSmsd
